CN113951284A - Antibacterial and antiviral plant compound essential oil and preparation method and application thereof - Google Patents
Antibacterial and antiviral plant compound essential oil and preparation method and application thereof Download PDFInfo
- Publication number
- CN113951284A CN113951284A CN202111131973.5A CN202111131973A CN113951284A CN 113951284 A CN113951284 A CN 113951284A CN 202111131973 A CN202111131973 A CN 202111131973A CN 113951284 A CN113951284 A CN 113951284A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- plant compound
- antibacterial
- antiviral
- compound essential
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 259
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 22
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 238000004140 cleaning Methods 0.000 claims abstract description 8
- 230000000249 desinfective effect Effects 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims description 63
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 18
- 244000166124 Eucalyptus globulus Species 0.000 claims description 18
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims description 18
- 240000003553 Leptospermum scoparium Species 0.000 claims description 18
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 18
- 241000723346 Cinnamomum camphora Species 0.000 claims description 16
- 244000179970 Monarda didyma Species 0.000 claims description 16
- 235000010672 Monarda didyma Nutrition 0.000 claims description 16
- 240000002505 Pogostemon cablin Species 0.000 claims description 16
- 235000011751 Pogostemon cablin Nutrition 0.000 claims description 16
- 244000223014 Syzygium aromaticum Species 0.000 claims description 16
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 15
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 13
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 13
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 12
- 235000011613 Pinus brutia Nutrition 0.000 claims description 12
- 241000018646 Pinus brutia Species 0.000 claims description 12
- 229960000846 camphor Drugs 0.000 claims description 11
- 229930008380 camphor Natural products 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 241001529744 Origanum Species 0.000 claims description 9
- 235000011203 Origanum Nutrition 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000002147 killing effect Effects 0.000 claims description 8
- 240000007673 Origanum vulgare Species 0.000 claims description 7
- 235000010677 Origanum vulgare Nutrition 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 241000723347 Cinnamomum Species 0.000 claims description 4
- 235000017803 cinnamon Nutrition 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 235000018782 Dacrydium cupressinum Nutrition 0.000 claims description 2
- 235000013697 Pinus resinosa Nutrition 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 240000006055 Dacrydium cupressinum Species 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 238000012360 testing method Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 8
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 8
- 241000711467 Human coronavirus 229E Species 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000050 ionisation spectroscopy Methods 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 240000005020 Acaciella glauca Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/24—Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/28—Myrtaceae [Myrtle family], e.g. teatree or clove
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/36—Rutaceae [Rue family], e.g. lime, orange, lemon, corktree or pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/013—Deodorant compositions containing animal or plant extracts, or vegetable material
Abstract
The invention provides an antibacterial and antiviral plant compound essential oil and a preparation method and application thereof. The plant compound essential oil has stronger volatility, and has the functions of sterilizing and disinfecting air when aromatic molecules are dispersed in the air, thereby playing the roles of cleaning the air and improving the environment.
Description
Technical Field
This application is a series of applications having application number 202010359473.6, which is incorporated herein by reference in its entirety. The invention relates to the technical field of plant essential oil, in particular to antibacterial and antiviral plant compound essential oil and a preparation method and application thereof.
Background
Influenza virus transmission is mainly mediated by coughing and sneezing of infected persons, and infection is more likely to occur in a crowded environment. More and more evidence shows that trace viruses can be retained on the surface of a desktop, a mobile phone or other objects and then spread by the contact of fingers with eyes, nose and mouth. If an article with influenza virus is touched and then touches its nose and mouth, it may also become infected.
At present, to block viral transmission, the following are mainly used: sodium hypochlorite ("84"), formaldehyde, ethanol, glutaraldehyde, potassium permanganate, ethylene oxide, peracetic acid, and other chemical solutions to disinfect goods and the environment. However, these chemicals cause damage and pollution to the environment, contact human skin or are inhaled into the body, and are very harmful to health.
Disclosure of Invention
In view of the above problems, the present invention has been made to provide an antibacterial and antiviral plant compound essential oil, a preparation method and use thereof, which overcome the above problems or at least partially solve the above problems.
The invention provides a plant compound essential oil, which comprises the following components: 5-20% of tea tree essential oil, 1-10% of cassia bark essential oil, 8-18% of bergamot essential oil, 10-50% of eucalyptus globulus essential oil, 1-10% of origanum vulgare essential oil, 1-5% of cinnamomum camphora essential oil, 5-15% of pogostemon cablin essential oil, 1-10% of clove essential oil and 1-10% of pine and red plum essential oil.
Optionally, the plant compound essential oil comprises the following components in parts by weight:
15% of tea tree essential oil, 5% of cassia bark essential oil, 13% of bergamot essential oil, 40% of eucalyptus globulus essential oil, 5% of origanum vulgaris essential oil, 3% of white camphor essential oil, 9% of patchouli essential oil, 5% of clove essential oil and 5% of pine and red plum essential oil. The components of the plant compound essential oil are all natural aromatic substances extracted from at least one part of roots, stems, leaves, flowers and fruits of plants by distillation and supercritical methods.
The invention also provides a preparation method of the antibacterial and antiviral plant compound essential oil, which comprises the following steps:
s1, cleaning and disinfecting containers, tools and inner packing materials for preparing the plant compound essential oil;
s2, weighing the raw materials for preparing the plant compound essential oil according to the proportion;
s3, sequentially adding the raw materials into a sterilized container, and uniformly stirring to obtain an essential oil finished product;
and S4, filling and subpackaging the finished essential oil product by using a packaging bottle.
Optionally, S5 is further included after S4, and after the packaged essential oil product is packaged by an outer package, a unique corresponding label is generated and submitted for inspection, so that the essential oil product is put in storage after the essential oil product is qualified.
Optionally, tea tree essential oil, cassia bark essential oil, bergamot essential oil, eucalyptus globulus essential oil, origanum vulgaris essential oil, camphor white essential oil, patchouli essential oil, clove essential oil and red plum essential oil are sequentially added into the container.
Optionally, the plant compound essential oil comprises the following raw materials in parts by weight: 5-20% of tea tree essential oil, 1-10% of cassia bark essential oil, 8-18% of bergamot essential oil, 10-50% of eucalyptus globulus essential oil, 1-10% of origanum vulgare essential oil, 1-5% of cinnamomum camphora essential oil, 5-15% of pogostemon cablin essential oil, 1-10% of clove essential oil and 1-10% of pine and red plum essential oil.
Optionally, the plant compound essential oil comprises the following raw materials in parts by weight: 15% of tea tree essential oil, 5% of cassia bark essential oil, 13% of bergamot essential oil, 40% of eucalyptus globulus essential oil, 5% of origanum vulgaris essential oil, 3% of white camphor essential oil, 9% of patchouli essential oil, 5% of clove essential oil and 5% of pine and red plum essential oil.
Alternatively, the stirring time of each constituent material in the vessel is 10 minutes.
Alternatively, the entire preparation process is carried out at room temperature.
The invention also provides application of the antibacterial and antiviral plant compound essential oil in a product for inhibiting and killing bacteria and viruses.
The invention also provides application of the antibacterial and antiviral plant compound essential oil in inhibiting and killing H1N1 virus products.
The plant compound essential oil provided by the invention takes tea tree essential oil, cassia bark essential oil, bergamot essential oil, eucalyptus globulus essential oil, origanum vulgaris essential oil, camphor essential oil, patchouli essential oil, clove essential oil and rose malus paniculatus essential oil as raw materials, the whole process of the preparation technology is carried out at normal room temperature, no catalyst, high temperature and other external means are used, and the product is completely and naturally generated. The plant compound essential oil has stronger volatility, and has the function of sterilizing and disinfecting air when aromatic molecules are dispersed in the air; thereby playing the roles of cleaning air and improving environment. The plant compound essential oil prepared by the invention has a good inhibition effect especially on the H1N 1A virus.
The foregoing description is only an overview of the technical solutions of the present invention, and the embodiments of the present invention are described below in order to make the technical means of the present invention more clearly understood and to make the above and other objects, features, and advantages of the present invention more clearly understandable.
The above and other objects, advantages and features of the present invention will become more apparent to those skilled in the art from the following detailed description of specific embodiments thereof, taken in conjunction with the accompanying drawings.
Drawings
Various other advantages and benefits will become apparent to those of ordinary skill in the art upon reading the following detailed description of the preferred embodiments. The drawings are only for purposes of illustrating the preferred embodiments and are not to be construed as limiting the invention. Also, like reference numerals are used to refer to like parts throughout the drawings. In the drawings:
FIG. 1 is a schematic diagram showing the preparation process of the antibacterial and antiviral plant compound essential oil according to the embodiment of the invention;
FIG. 2 shows plant compound essential oil No. 1 EC according to the embodiment of the invention50Fitting a curve;
FIG. 3 shows the plant compound essential oil No. 1 CC according to the embodiment of the invention50Fitting a curve;
FIG. 4 shows plant compound essential oil No. 2 EC according to the embodiment of the invention50Fitting a curve;
FIG. 5 shows a plant compound essential oil No. 2 CC according to an embodiment of the invention50Fitting a curve;
FIG. 6 shows plant compound essential oil No. 3 EC according to the embodiment of the invention50Fitting a curve;
FIG. 7 shows oseltamivir acid EC according to an embodiment of the present invention50Fitting a curve fitting curve;
FIG. 8 shows a schematic diagram for comparing TI values of plant compound essential oil against influenza A virus strain H1N1/PR 8.
Detailed Description
Exemplary embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. While exemplary embodiments of the invention are shown in the drawings, it should be understood that the invention can be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The embodiment of the invention provides an antibacterial and antiviral plant compound essential oil, which comprises the following components: 5-20% of tea tree essential oil, 1-10% of cassia bark essential oil, 8-18% of bergamot essential oil, 10-50% of eucalyptus globulus essential oil, 1-10% of origanum vulgare essential oil, 1-5% of cinnamomum camphora essential oil, 5-15% of pogostemon cablin essential oil, 1-10% of clove essential oil and 1-10% of pine and red plum essential oil. Preferably, the ratio of the components is as follows: 15% of tea tree essential oil, 5% of cassia bark essential oil, 13% of bergamot essential oil, 40% of eucalyptus globulus essential oil, 5% of origanum vulgaris essential oil, 3% of white camphor essential oil, 9% of patchouli essential oil, 5% of clove essential oil and 5% of pine and red plum essential oil.
Each raw material component in the plant compound essential oil provided by the embodiment is a pure natural aromatic substance extracted from roots, stems, leaves, flowers, fruits and other parts of plants by methods such as distillation, supercritical extraction and the like; the essential oil has stronger volatility, and the aromatic molecules also have the function of sterilizing and disinfecting air when being dispersed in the air; therefore, the plant essential oil has the functions of cleaning air and improving the environment.
Optionally, an embodiment of the present invention further provides a preparation method of the plant compound essential oil, as shown in fig. 1, the preparation method of the plant compound essential oil may include:
s1, cleaning and disinfecting each container, tool and inner packaging material for preparing the plant compound essential oil.
S2, weighing the raw materials for preparing the plant compound essential oil according to the proportion.
And S3, sequentially adding the raw materials into the sterilized container, and uniformly stirring to obtain the finished essential oil. Specifically, the tea tree essential oil, the cinnamon essential oil, the bergamot essential oil, the eucalyptus globulus essential oil, the origanum vulgaris essential oil, the camphor tree essential oil, the patchouli essential oil, the clove essential oil and the red pine essential oil can be sequentially added into a container for mixing and stirring for 10 minutes.
And S4, filling and subpackaging the finished essential oil product by using a packaging bottle. The amount dispensed required 30ml (about 28g), tolerance ± 2.4 ml.
Furthermore, an outer package can be added for the packaged essential oil, labeling and code spraying are carried out, and the essential oil is sent for inspection and then enters a finished product warehouse after being inspected to be qualified.
The plant compound essential oil provided by the embodiment is named as 'aromatic armor III', the whole preparation process is carried out at normal room temperature, and no catalyst, high temperature and other external means are used, so that the product is completely and naturally generated. The raw material components are tea tree essential oil, cassia bark essential oil, bergamot essential oil, blue gum eucalyptus essential oil, origanum essential oil, camphor white essential oil, patchouli essential oil, clove essential oil and pine red plum essential oil. The plant compound essential oil prepared by the embodiment has stronger volatility, and has the function of sterilizing and disinfecting air when aromatic molecules are dispersed in the air; therefore, the plant essential oil has the functions of cleaning air and improving the environment. Particularly, when in use, the paint can be sprayed on the surfaces of articles such as office supplies, furniture, clothes and the like; can be sprayed in the air or on the surface of an article by a sprayer and the like; spreading fragrance with fragrance spreading instrument, or dripping onto the surface of the object, and smearing with paper towel.
The following describes the detection of the antibacterial and antiviral effects of the plant compound essential oil provided by the invention through several preferred embodiments.
Example one
Preparing plant compound essential oil No. 1, wherein the blue gum Eucalyptus essential oil is 30 parts, the tea tree essential oil is 20 parts, the anise essential oil is 12 parts, the cinnamon essential oil is 5 parts, the lavender essential oil is 2 parts, the lemon grass essential oil is 4 parts, and the mint essential oil is 10 parts.
Preparing plant compound essential oil No. 2, wherein tea tree essential oil 50%, lavender essential oil 9%, rosemary essential oil 0.5%, blue gum Eucalyptus 35%, mint 5%, and thyme 0.5%.
Preparing plant compound essential oil No. 3 (the plant compound essential oil provided by the embodiment of the invention), wherein the tea tree essential oil is 15%, the cinnamon essential oil is 5%, the bergamot essential oil is 13%, the eucalyptus globulus essential oil is 40%, the origanum vulgare essential oil is 5%, the white camphor essential oil is 3%, the patchouli essential oil is 9%, the clove essential oil is 5% and the pine and red plum essential oil is 5%.
Antiviral experiments were performed using the essential oil composition of the above formulation.
First, experiment purpose
The effect of the essential oil composition with different formulas on resisting influenza A virus H1N1/PR8 strain is evaluated in vitro.
Materials and methods
2.1 test substances
Subject name: essential oil composition No. 1, 2, 3.
Storage conditions of the test substance: at 2-8 deg.c and in dark.
2.2 materials of the experiment
Influenza a virus strain PR8 (central research center for antiviral engineering of traditional Chinese medicine of Shandong university of traditional Chinese medicine) type H1N 1. MDCK canine kidney cells (center for disease prevention and control in Shandong province). DMEM culture medium (batch No. 8120245, Gibco, USA), fetal bovine serum (batch No. 2022057, Biological Industries, Israel), pancreatic enzyme solution-EDTA phenol red (batch No. 2120734, Gibco, USA), Opti-MEM (batch No. 2152782, Gibco, USA). Oseltamivir acid (batch: HY-17016MedChemexpress, USA).
A multifunctional real-time label-free cell analyzer (asen, ACEA, usa), a high-pressure steam sterilization pot (MJ-78A, schnakai instruments equipment (shanghai) ltd.), a carbon dioxide incubator (HF90, likang BIO-medical science and technology control ltd.), an inverted microscope (CKX41, japan OLYMPUS), a biosafety cabinet (HFsafe-1200LC, likang BIO-medical science and technology control ltd.), a cell counter (TC20, BIO-RAD).
2.3 Experimental methods
2.3.1 real-time monitoring System for cells to determine toxicity of essential oil composition No. 1-3 to MDCK cells
The real-time label-free cell analysis (RTCA) technique is a real-time cell monitoring technique based on the microelectronic impedance technique, and takes the Cell Index (CI) as an evaluation index, and the calculation formula is as follows:
where Rn is the electrode impedance for cells adherent to the well, Rb is the baseline impedance for media only before cells are added to the well, and CI depends on the size, shape, number, and adhesion of the cells. The technology does not need a marker, and can dynamically observe the growth change of the cells continuously for several days in real time. The procedures of the RTCA xCEELLigene system are shown in Table 1. Determination of half-maximal toxicity concentration (CC) of essential oil composition No. 1-3 on MDCK cells50). The specific operation steps are as follows:
1) 50 μ L of medium was added to the wells of E-plate 16.
2) The E-plate16 was placed at 37 ℃ in 5% CO2At rtca station in a thermostated incubator.
3) The RTCA system will automatically scan ("ScanPlate") to see if the contact is good (ConnectionOK is shown on the "Message" page).
4) Baseline (backsground) testing was initiated to determine that the selected wells were in normal contact and that all wells had CI values below 0.063.
5) E-plate16 was removed and 100. mu.L of DCK cell suspension was added to the wells to give 5000 cells/100. mu.L cells per well.
6) The E-plate16 was placed in a clean bench at room temperature for 30 min.
7) The E-plate16 was placed at 37 ℃ in 5% CO2And clicking the starting system on the RTCAStation in the constant temperature incubator to start automatic scanning, and running Step 2.
8) After the system auto-scans "ScanPlate", Step2 was started (overnight check cell proliferation curve). After the cells have entered the plateau, Step2 is terminated and the E-plate16 is removed from the RTCASTATION.
9) The culture broth was discarded. A series of 100. mu.L of the prepared concentration gradient essential oils No. 1-3 were pipetted into the cells along the wells A to G. The drug formulations were prepared with 2% FBS DMEM, so 2% FBS DMEM in wells H served as the normal control. The concentration gradient of the essential oil No. 1 is as follows: 3322.86, 1661.43, 830.72, 415.36, 207.68, 103.84 and 51.92 mu g/mL. The concentration gradient of the essential oil No. 2 is as follows: 5366.5, 2683.25, 1341.63, 670.81, 335.41, 167.70 and 83.85 mu g/mL. The aromatic armour essential oil No. 3 concentration gradient is as follows: 2480.75, 1240.38, 620.19, 310.09, 155.05, 77.52 and 38.76 mu g/mL. The concentration gradient of the oseltamivir acid is as follows: 100. mu.M, 50. mu.M, 25. mu.M, 12.5. mu.M, 6.25. mu.M, 3.125. mu.M, 1.56. mu.M.
10) The E-plate16 was placed on the RTCASTATION in the incubator and the autoscan was started by clicking the Start System, running Step3 and Step 4.
CC50The calculation formula is as follows: sigmoidal-response (Variableslope-)
TABLE 1RTCA xCELLigence System program
2.3.2 cell real-time monitoring System for determining protective action of essential oil composition No. 1-3 on influenza virus infected MDCK cell
Determination of the half Effective Concentration (EC) of essential oil No. 1-3 on influenza virus infected MDCK cells50) The specific operation steps are as follows:
1) baseline measurements were taken and the cell plating step was the same as the first 8) under "2.1". The procedures of the RTCAXCELLLigence system are shown in Table 1.
2) After the cells entered the plateau phase, the culture medium was discarded. Setting a drug intervention group, a virus control group and a normal control group. Wells a-F were drug intervention groups, 100 μ L each of the essential oil compositions 1 to 3 prepared in a series of concentration gradients was pipetted into the cells along wells a to F, 100 μ L of H1N1 type PR8 strain influenza virus was added at a diluted concentration with a multiplicity of infection of 0.1(MOI, multiplicityof infection), and 2 wells were repeated for each concentration. Well G was a control group of virus, 100. mu.L of virus + 100. mu.L of LOpti-MEM (containing 1. mu.g/ml of Trypsin pancreatin, the same applies below). Well H was a normal control, 200. mu. LOpti-MEM. The essential oil composition No. 1 has the concentration gradient that: 3110. 1560, 778.35, 389.18, 194.59, 97.29 and 48.65 mu g/mL. The concentration gradient of the essential oil composition No. 2 is as follows: 5500. 2750, 1370, 687.45, 343.73, 171.86 and 85.93 mug/mL. The essential oil composition No. 3 has the concentration gradient that: 3040. 1520, 761.25, 380.63, 190.31, 95.16, 47.58 μ g/mL.
3) The RTCAT system will automatically scan ("ScanPlate") to see if the contact is good (ConnectionOK is shown on the "Message" page) by replacing E-plate16 on the RTCAState.
4) Start Step3 and Step
EC50The calculation formula is as follows: sigmoidal-response (Variableslope)
TI＝CC50/EC50
Third, experimental results
3.1 essential oil composition No. 1
Table 2 essential oil composition No. 1 measurement results
FIG. 2 and FIG. 3 show the essential oil composition No. 1 EC, respectively50Fitting curve and CC50And (6) fitting a curve.
3.1 essential oil composition No. 2
Table 3 essential oil composition No. 2 measurement results
FIG. 4 and FIG. 5 show the essential oil composition No. 2 EC, respectively50Fitting curve and CC50And (6) fitting a curve.
3.3 essential oil composition No. 3
Table 4 essential oil composition No. 3 measurement results
Figure 6 shows essential oil composition No. 3 EC50And (6) fitting a curve.
3.4 Oseltamivir acid
TABLE 5 results of Oseltamivir acid determination
FIG. 7 shows oseltamivir EC50And (6) fitting a curve. Since 200. mu.M of oseltamivir at the maximum concentration did not exhibit cytotoxicity, 200. mu.M was used as CC50To calculate.
FIG. 8 is a graph showing the comparison of TI values of the essential oil composition against influenza A virus strain H1N1/PR 8.
Fourth, conclusion of experiment
The method of RTCA can be used for continuously monitoring the proliferation influence of the drug on virus infected MDCK, thereby accurately and comprehensively reflecting the antiviral effect of the drug. Experiments show that the highest selection index TI value of the positive control drug (oseltamivir acid) can reach 248.63, and the positive control drug shows a strong in-vitro antiviral effect. The essential oil composition No. 1, No. 2 and No. 3 show certain drug effect against influenza A virus H1N1 in vitro, wherein the essential oil composition No. 3 shows stronger effect, and the selection index TI value is 157.81. Therefore, the essential oil composition No. 3 has good in-vitro antiviral effect.
The following shows the cases of the two examples and the three examples of the plant compound essential oil of the present invention that have been tested for the antibacterial and antiviral effects against streptococcus pneumoniae and coronavirus HCoV-229E, and it should be noted that the plant compound essential oil has different components and formulations from the essential oil described in patent 202010359473.6, but can also have good inhibitory effects against streptococcus pneumoniae and coronavirus.
Example two
Preparing plant compound essential oil, wherein the tea tree essential oil is 18%, the cassia bark essential oil is 6%, the bergamot essential oil is 10%, the eucalyptus globulus essential oil is 30%, the origanum vulgare essential oil is 8%, the white camphor essential oil is 4%, the patchouli essential oil is 12%, the clove essential oil is 6% and the pine and red plum essential oil is 6%.
The antibacterial effect of Streptococcus pneumoniae is detected by Engel authentication detection group (ICAS) and Engel detection technology service (Shanghai) of the plant formula essential oil, and a detection report numbered SHC20020273-01AR is obtained in 24/4 of 2020.
Test concentration: stock solution
Acting time: 10 minutes
TABLE 6 test results
According to the test results in table 6, the plant compound essential oil prepared in this embodiment has a good inhibitory effect on streptococcus pneumoniae.
EXAMPLE III
Preparing plant compound essential oil, wherein the tea tree essential oil accounts for 10%, the cassia bark essential oil accounts for 6%, the bergamot essential oil accounts for 15%, the eucalyptus globulus essential oil accounts for 35%, the origanum vulgare essential oil accounts for 7%, the white camphor essential oil accounts for 4%, the patchouli essential oil accounts for 10%, the clove essential oil accounts for 6% and the pine and red plum essential oil accounts for 7%.
The coronavirus HCoV-229E killing test of the plant formula essential oil is carried out by the Invitrogen certification and detection technology service (Shanghai) of the Invitrogen (ICAS), and a detection report with the number of SHC20020273-01B is obtained in 14.4.2020.
And (3) testing items: coronavirus HCoV-229E kill test (10 minutes)
The test method comprises the following steps: reference to Disinfection Specification 2002 edition
The test results are shown in tables 7 and 8. The unit of data for the first to third tests and the average values in Table 8 is Log (TCID 50/ml).
TABLE 7 coronavirus HCoV-229E killing effect and log killing value of plant compound essential oil composition
TABLE 8 mean inactivated Virus Rate
Test results
Under the experimental conditions set by the test, the test sample reacts with the coronavirus HCoV-229E suspension for 10 minutes, and the plant compound essential oil prepared in the embodiment has a certain effect of killing the coronavirus HCoV-229E.
Through analysis of the experimental results, the plant compound essential oil provided by the embodiment of the invention can effectively inhibit coronavirus and streptococcus pneumoniae, and particularly has a good antiviral effect on H1N1 influenza A virus, and the plant compound essential oil provided by the embodiment of the invention does not use any catalyst, high temperature and other external means, can completely and naturally generate a product, has no side effect when being used by a user, and has the effects of cleaning air and improving the environment.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments can be modified or some or all of the technical features can be equivalently replaced within the spirit and principle of the present invention; such modifications or substitutions do not depart from the scope of the present invention.
Claims (10)
1. The antibacterial and antiviral plant compound essential oil is characterized by comprising the following components: 5-20% of tea tree essential oil, 1-10% of cassia bark essential oil, 8-18% of bergamot essential oil, 10-50% of eucalyptus globulus essential oil, 1-10% of origanum vulgare essential oil, 1-5% of cinnamomum camphora essential oil, 5-15% of pogostemon cablin essential oil, 1-10% of clove essential oil and 1-10% of pine and red plum essential oil.
2. The plant compound essential oil as claimed in claim 1, wherein the plant compound essential oil comprises the following components in parts by weight:
15% of tea tree essential oil, 5% of cassia bark essential oil, 13% of bergamot essential oil, 40% of eucalyptus globulus essential oil, 5% of origanum vulgaris essential oil, 3% of white camphor essential oil, 9% of patchouli essential oil, 5% of clove essential oil and 5% of pine and red plum essential oil.
3. The plant compound essential oil as claimed in claim 1, wherein the components of the plant compound essential oil are pure natural aromatic substances extracted from at least one part of roots, stems, leaves, flowers and fruits of plants by a distillation and supercritical method.
4. A method for preparing the antibacterial and antiviral plant compound essential oil as claimed in any one of claims 1 to 3, which comprises:
s1, cleaning and disinfecting containers, tools and inner packing materials for preparing the plant compound essential oil;
s2, weighing the raw materials for preparing the plant compound essential oil according to the proportion;
s3, sequentially adding the raw materials into a sterilized container, and uniformly stirring to obtain an essential oil finished product;
and S4, filling and subpackaging the finished essential oil product by using a packaging bottle.
5. The method of claim 4, wherein the tea tree essential oil, the cinnamon essential oil, the bergamot essential oil, the eucalyptus globulus essential oil, the origanum vulgaris essential oil, the camphor essential oil, the patchouli essential oil, the clove essential oil and the red pine essential oil are sequentially added to the container in this order.
6. The method of claim 4, wherein the stirring time of each constituent material in the vessel is 10 minutes.
7. The method according to claim 4, wherein the entire preparation process is carried out at room temperature.
8. The method according to any one of claims 4-7, further comprising:
and S5, packaging the subpackaged essential oil products by utilizing an outer package, generating a unique corresponding label and performing inspection, and warehousing and storing after the products are qualified.
9. Use of the antibacterial and antiviral plant compound essential oil as defined in any one of claims 1-2 in a product for inhibiting and killing bacteria and viruses.
10. The use of the antibacterial and antiviral plant compound essential oil as claimed in any one of claims 1 to 2 in a product for inhibiting and killing H1N1 virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111131973.5A CN113951284A (en) | 2021-09-26 | 2021-09-26 | Antibacterial and antiviral plant compound essential oil and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111131973.5A CN113951284A (en) | 2021-09-26 | 2021-09-26 | Antibacterial and antiviral plant compound essential oil and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113951284A true CN113951284A (en) | 2022-01-21 |
Family
ID=79462294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111131973.5A Pending CN113951284A (en) | 2021-09-26 | 2021-09-26 | Antibacterial and antiviral plant compound essential oil and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113951284A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115836995A (en) * | 2022-08-15 | 2023-03-24 | 科丝美诗(上海)检测科技有限公司 | Preparation method of Manuka tree extract and application of Manuka tree extract in cosmetics |
| WO2024028179A1 (en) * | 2022-08-04 | 2024-02-08 | Juan Antonio Santisteban Ortiz | Biocidal composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036052A1 (en) * | 1998-01-16 | 1999-07-22 | Morice Andre Pierre | Mixture containing honey, at least one essential oil and/or at least one essential oil derivative |
| CN111407859A (en) * | 2020-04-29 | 2020-07-14 | 北京天然风尚健康科技有限公司 | Preparation method and application of armor essential oil composition with antibacterial and antiviral effects |
| CN112891477A (en) * | 2020-04-29 | 2021-06-04 | 北京天然风尚健康科技有限公司 | Preparation method and application of antibacterial and antiviral aromatic armour essential oil composition |
-
2021
- 2021-09-26 CN CN202111131973.5A patent/CN113951284A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036052A1 (en) * | 1998-01-16 | 1999-07-22 | Morice Andre Pierre | Mixture containing honey, at least one essential oil and/or at least one essential oil derivative |
| CN111407859A (en) * | 2020-04-29 | 2020-07-14 | 北京天然风尚健康科技有限公司 | Preparation method and application of armor essential oil composition with antibacterial and antiviral effects |
| CN112891477A (en) * | 2020-04-29 | 2021-06-04 | 北京天然风尚健康科技有限公司 | Preparation method and application of antibacterial and antiviral aromatic armour essential oil composition |
Non-Patent Citations (2)
| Title |
|---|
| （英）苏珊·柯蒂斯 著: "《芳香精油宝典》", 30 November 2018, 中国轻工业出版社 * |
| 田景振 等著: "《抗病毒中草药的研究与应用》", 30 April 2019, 山东科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024028179A1 (en) * | 2022-08-04 | 2024-02-08 | Juan Antonio Santisteban Ortiz | Biocidal composition |
| CN115836995A (en) * | 2022-08-15 | 2023-03-24 | 科丝美诗(上海)检测科技有限公司 | Preparation method of Manuka tree extract and application of Manuka tree extract in cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113951284A (en) | Antibacterial and antiviral plant compound essential oil and preparation method and application thereof | |
| AU2016202043B2 (en) | Peracetic acid vapor sterilization of food and beverage containers | |
| Perrut | Sterilization and virus inactivation by supercritical fluids (a review) | |
| JP4278199B2 (en) | Composition having the synergistic effect of peracetic acid and amine oxide, its use and method for disinfecting hard surfaces thereby | |
| DK2391391T3 (en) | Method of sterilization | |
| Villa et al. | Hydrogels in hand sanitizers | |
| WO2018024087A1 (en) | Air purification disinfectant and preparation method | |
| Bueno | Models of evaluation of antimicrobial activity of essential oils in vapour phase: a promising use in healthcare decontamination | |
| WO2013037014A1 (en) | Disinfectant compositions and uses thereof | |
| Farrugia et al. | Effect of sterilization techniques prior to antimicrobial testing on physical properties of dental restorative materials | |
| CN109497106B (en) | Preparation method of foam disinfectant | |
| Soto et al. | Antimicrobial effect and cytotoxic activity of vinegar-hydrogen peroxide mixture: A possible alternative for denture disinfection | |
| CN111407859A (en) | Preparation method and application of armor essential oil composition with antibacterial and antiviral effects | |
| Noda et al. | Evaluation of low-temperature sterilization using hydrogen peroxide gas containing peracetic acid | |
| KR102127417B1 (en) | Compositions for sterilization and disinfection using hydrogen peroxide | |
| Janani et al. | Cytotoxicity of oregano essential oil and calcium hydroxide on L929 fibroblast cell: A molecular level study | |
| CN110721103A (en) | Chinese herbal medicine essential oil bacteriostatic skin-care washing-free hand sanitizer and preparation method thereof | |
| CN110477792A (en) | A kind of nonalcoholic wet tissue and preparation method thereof can be used for breathing mask cleaning-sterilizing | |
| CN104940063A (en) | Medical liquid soap | |
| JPS59157007A (en) | Disinfectant | |
| Choi et al. | Influence of chlorine and mode of application on efficacy of aqueous solutions of 1-methylcyclopropene in delaying tomato (Solanum lycopersicum L.) fruit ripening | |
| Zhang et al. | Novel chlorine‐extending polymer coating with prolonged antiviral activity against SARS‐CoV‐2 | |
| CN107987133B (en) | Small molecule polypeptide and application thereof | |
| CN107892712B (en) | Small molecule polypeptide and application thereof | |
| KR20180023747A (en) | Natural antibacterial composition usable wet oral tissue for the child, the old or the infirm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220121 |
|
| RJ01 | Rejection of invention patent application after publication |